This review deals with the clinical, basic and genetic aspects of a recently highlighted form of idiopathic ventricular fibrillation known as the Brugada syndrome. Our primary objective in this review is to identify the full scope of the syndrome and attempt to correlate the electrocardiographic manifestations of the Brugada syndrome with cellular and ionic heterogeneity known to exist within the heart under normal and pathophysiologic conditions so as to identify the cellular basis and thus potential diagnostic and therapeutic approaches. The available data suggest that the Brugada syndrome is a primary electrical disease resulting in abnormal electrophysiologic activity in right ventricular epicardium. Recent genetic data linking the Brugada syndrome to an ion channel gene mutation (SCN5A) provides further support for the hypothesis. The electrocardiographic manifestations of the Brugada syndrome show transient normalization in many patients, but can be unmasked using sodium channel blockers such as flecainide, ajmaline or procainamide, thus identifying patients at risk. The available data suggest that loss of the action potential dome in right ventricular epicardium but not endocardium underlies the ST segment elevation seen in the Brugada syndrome and that electrical heterogeneity within right ventricular epicardium leads to the development of closely coupled premature ventricular contractions via a phase 2 reentrant mechanism that then precipitates ventricular tachycardia/ventricular fibrillation (VT/VF). Currently, implantable cardiac defibrillator implantation is the only proven effective therapy in preventing sudden death in patients with the Brugada syndrome and is indicated in symptomatic patients and should be considered in asymptomatic patients in whom VT/VF is inducible at time of electrophysiologic study.
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In the United States alone, sudden death due to cardiac arrest occurs with an incidence of more than 300,000 per year (1) . Recent interest has focused on unexpected arrhythmogenic death occurring in individuals with minimal or no structural heart disease, estimated to represent 3% to 9% of out-ofhospital cases of ventricular fibrillation unrelated to myocardial infarction (2) . In addition to the ventricular preexcitation syndrome and the long QT syndrome, a new electrocardiographic (ECG) marker of sudden death in otherwise healthy individuals has been identified. Referred to as the Brugada syndrome, clinical cases have been reported in countries worldwide . World Wide Web Home Page for the Brugada syndrome has been introduced on the Internet (54) .
The Brugada syndrome is characterized by a) a peculiar ST segment elevation in the right precordial leads often accom-panied by apparent conduction block in the right ventricle, b) structurally normal heart and c) a propensity for lifethreatening ventricular tachyarrhythmias. Originally described by Pedro and Josep Brugada as "right bundle branch block and persistent ST segment elevation in V 1 -V 3 " in patients with no apparent structural heart disease, this ECG abnormality and its role in malignant arrhythmogenicity has become the subject of increasing attention and controversy. Transient forms of the disease in which the ECG manifestations normalize for a period of time have been described more recently (17, 19, 40, 41, 43) . The prevalence of ventricular fibrillation (VF) associated with this ECG phenomenon have been estimated in some countries as high as 40% to 60% of all cases of idiopathic VF (55) . Certain electrophysiologic similarities have been found between ECG markers of the Brugada syndrome, early repolarization syndrome (56 -58) and hypothermia (59 -62) . A strong link has been identified between the Brugada syndrome and sudden and unexpected death syndrome in Southeast Asian men (17, 29, 24) . Possible overlap with arrhythmogenic right ventricular dysplasia (ARVD) and apoptosis has been suggested (7) (8) (9) 11, 33) , although the Brugada syndrome and ARVD appear to be caused by defects in different chromosomal loci. An ion channel defect resulting in heterogeneous loss of the action potential dome in right ventricular epicardium has been proposed as a mechanism underlying both idiopathic ST segment elevation in the right precordial leads and the dispersion of repolarization that predisposes the heart to the development of malignant reentrant ventricular arrhythmias (59 -61) . Recent genetic data linking the Brugada syndrome to an ion channel gene mutation provides further support for the hypothesis that the Brugada syndrome is a primary electrical disease (55) .
Our primary objective in this review is to identify the full scope of this syndrome and attempt to correlate the electrocardiographic manifestations of the Brugada syndrome with cellular and ionic heterogeneity known to exist within the heart under normal and pathologic conditions so as to identify the cellular basis and thus potential diagnostic and therapeutic approaches.
Electrocardiographic Markers of the Brugada Syndrome
In 1991-1992 Pedro and Josep Brugada described eight otherwise healthy patients with sudden and aborted cardiac death, in whom they found "right bundle branch block and persistent ST segment elevation in leads V 1 -V 3 " (3, 4) . Based on those clinical cases they outlined a new "distinct clinical and electrocardiographic syndrome," which has subsequently been called the Brugada syndrome.
The electrocardiographic pattern of ST segment elevation and inversion of the T wave in the right precordial leads with and without right bundle branch block (RBBB) have been described in apparently healthy individuals since 1953 (63) (64) (65) (66) (67) . This striking ECG phenomenon had been largely ignored until Martini et al. (7) and Aihara et al. (24) brought attention to a possible link between this ventricular repolarization abnormality and sudden death in their patients.
The QRS complex in the Brugada syndrome ends with a positive deflection (or prominent J wave) followed by an elevated down-sloping ST segment and a negative T wave with a normal (38) or even short (24) QT interval. Leads V 1 to V 3 show the most prominent changes, with the degree of ST segment elevation tapering off in adjacent leads and often associated with varying degrees of conduction block in the right bundle branch. In lead V 1 , the terminal portion of the QRS complex is elevated as an rЈ or a J wave followed by a down-sloping ST segment ending in a negative deflection. In adjacent leads the changes may be similar, but often the ST segment elevation is more horizontal and less prominent. It is a characteristic finding that the ST segment elevation in the right precordial leads is not accompanied by reciprocal ST segment depression in opposite leads ( Fig. 1A ). Repolarization abnormalities are often more prominent in the right chest leads placed on intercostal space higher than usual (42) . Clinicians have identified this "bizarre, extremely special form of ST segment elevation" (13) as: a) major (coved type or dome shape), b) minor (saddle-back type) and c) triangular (31) . Whereas a) is related to acute episodes of electrical instability, b) is thought to be due to a chronic course of the disease (47) .
ST segment elevation in the right chest leads is observed in a variety of clinical and experimental settings ( Table 1 ) and is not unique or highly specific for the Brugada syndrome. A clear distinction cannot be made on the basis of an ECG alone. However, ST segment elevation in the right precordial leads in the absence of ischemia, electrolyte or metabolic disorders, pulmonary or inflammatory diseases or abnormalities of central or peripheral nervous system may identify the Brugada syndrome. In such cases, the term "idiopathic" is appropriate.
The prevalence of idiopathic ST segment elevation is reported to be 2.1% to 2.65% (14) . An elevated ST segment limited to the right precordial leads occurs in less than 1% of all cases of elevated ST segment (68) . The combination of ST segment elevation in these leads and RBBB was found in 12 out of 22,027 subjects in Japan (0.05%). All 12 individuals were male with no structural heart disease; four had a history of sudden cardiac death (39) . Sixty-three patients (60 male) with RBBB, persistent ST segment elevation and a normal QT interval are currently being followed in 34 medical centers in Japan. So far, 12 have experienced episodes of syncope and 17 suffered ventricular fibrillation (35, 47) .
In many patients with the Brugada syndrome, the ECG manifestations transiently normalize (40, 41, 43) , leading to underdiagnosis of the syndrome (38) . Strong sodium channel blockade using agents such as procainamide, ajmaline and flecainide can unmask the ST segment elevation in V 1 -V 3 and right bundle branch block-like pattern in many patients (61) . A number of other agents, including adrenergic and cholinergic neurohormones, are capable of modulating the degree of ST segment elevation in Brugada syndrome patients. Betaadrenoreceptor stimulation and alpha-adrenoreceptor blockade reduce the magnitude of ST segment elevation, but not necessarily the degree of conduction delay in the right ventricle in patients with the Brugada syndrome, whereas betaadrenergic blockade, alpha-adrenergic stimulation, sodium channel blockade and muscarinic stimulation augment the ST segment elevations (29, 42, 50) . More prominent ST segment elevation in the right chest leads (but not RBBB) has been observed immediately before (49,70) ( Fig. 1B) and after Abbreviations and Acronyms ARVD ϭ arrhythmogenic right ventricular dysplasia ECG ϭ electrocardiographic ERS ϭ early repolarization syndrome I Ca ϭ calcium current ICD ϭ implantable cardiac defibrillator I K-ATP ϭ adenosine triphosphate-sensitive potassium current I Na ϭ sodium current I to ϭ transient outward current RBBB ϭ right bundle branch block SUDS ϭ sudden and unexplained death syndrome TdP ϭ Torsade de Pointes VF ϭ ventricular fibrillation VT ϭ ventricular tachycardia episodes of aborted sudden cardiac death in some patients (29, 35) . The role of RBBB in the Brugada syndrome has been a matter of some controversy. In surveying 80 published ECGs obtained from patients with the Brugada syndrome, we found that at least one third of those classified as RBBB did not meet the ECG criteria for RBBB. Kasanuki et al., using bodysurface mapping, demonstrated a conduction delay in the anterior wall and RV outflow tract in six patients with the Brugada syndrome, only when a secondary R wave was present in lead V 1 (29) . Prolongation of the H-V interval has been documented in many clinical cases (4, 15, 28, 50) . However, there appears to be no correlation between RBBB and sudden cardiac death (69), whereas a definite link exists between the magnitude of ST segment elevation and incidence of the life-threatening arrhythmic events in patients with the Brugada syndrome. Thus, conduction delay in the right ventricle may be associated with the Brugada syndrome, but does not appear to be an integral part of the syndrome.
Brugada Syndrome and Early Repolarization Syndrome
Early repolarization syndrome (ERS), although characterized by idiopathic ST segment elevation, is different from the Brugada syndrome in that it is generally not associated with arrhythmias.
Electrocardiographically, both syndromes resemble a pattern of reversed Wolff-Parkinson-White syndrome with distinct slur or notch on the downstroke of the R wave. However, the elevated ST segment in ERS can be differentiated from ST segment elevation in the Brugada syndrome by its localization and pattern. The elevated ST segment in ERS is usually localized in leads V 2 to V 4 (5) and has an upward concavity with positive T wave polarity accompanied by a notched J point (71) , whereas ST segment elevation in the Brugada syndrome is limited to the right precordial leads, is slowly down-sloping and is followed by a negative T wave.
Electrophysiologically, ERS and the Brugada syndrome share some common mechanisms of drug-and neuromodula- The right precordial leads, V 1 to V 3 , display a down-sloping ST segment elevation. QRS is normal but QT dispersion between V 2 and V 6 is larger than normal (120 ms). (B) Selfterminating polymorphic ventricular tachycardia (continuous recording) in a patient with the Brugada syndrome. Closely coupled premature ventricular contractions precede the onset of tachyarrhythmia. Note the disappearance of the repolarization abnormalities following the arrhythmia. tion. As with the Brugada syndrome, isoproterenol is known to reduce or even eliminate the ST segment elevation in individuals with ERS, whereas propranolol increases the magnitude of ST segment elevation (56) .
Interestingly, ERS-like isoproterenol-sensitive ST segment elevation often appears on ECGs of patients with high (cervical) spinal cord injury (C 5 to C 6 ). In contrast to patients with lower spinal cord injury, injury to the cervical cord may completely disrupt cardiac sympathetic influence from higher centers, whereas parasympathetic control remains intact, suggesting that inadequate sympathetic tone in the presence of parasympathetic control of the heart may play a role in generation of the ST segment elevation (72) . This observation was confirmed in experiments with spinal cord compression in cats (73) and monkeys (74).
Brugada Syndrome and Sudden and Unexpected Death Syndrome
Sudden and unexpected death of young adults during sleep is endemic to Japan and Southeast Asia. The incidence of sudden and unexpected death syndrome (SUDS) among Asians living in the USA varies among different ethnic groups from 1:2,500 to 1:1,087 (19, 75, 76) . SUDS characteristics include the following: 1) victims are relatively young healthy men leading normal lives; 2) death often occurs during sleep late at night, and 3) autopsy findings are usually negative (77 
Brugada Syndrome and Arrhythmogenic Right Ventricular Dysplasia
The nature of the primary defect in the Brugada syndrome, whether cardiac or extracardiac, structural or functional, has also been a topic of debate. It has been suggested that the Brugada syndrome may represent either: a) a functional abnormality of the electrical activity of the heart or a primary electrical disease (34, 37, 38, 59, 60) ; or b) an early subclinical manifestation of right ventricular dysplasia/cardiomyopathy (2, (7) (8) (9) 33) .
Some investigators report remarkable myocardial atrophy with adipose tissue or fibrofatty infiltration in the dilated right ventricle (often involving the conducting tissue), consistent with ARVD, in all of their patients with the Brugada syndrome, whereas others report no structural defects whatsoever in any patient with the same syndrome. In this regard, it is important to emphasize that at the present time we do not have a gold standard for clinical or histologic diagnosis of ARVD. There is no controlled study that examines either the sensitivity or specificity of postmortem findings, quantitative evaluation of the fatty infiltration or the degree of fibrotic tissue involvement (37) . The Brugada syndrome, like ARVD, is also consistent with autosomal dominant inheritance with variable expression (22) . However, it is not related to any gene abnormality so far described for ARVD (78, 79) . It seems premature to draw any definitive conclusions as to whether the Brugada syndrome is or is not an atypical or early manifestation of the ARVD.
It is intriguing to speculate that the Brugada syndrome may start out as a primary electrical disease, but chronically progress to develop structural abnormalities. This hypothesis is suggested by the observation that electrical remodeling in atrial fibrillation and ventricular hibernation precedes structural remodeling (80). Isolated sheets of canine ventricular epicardium exposed to potassium channel openers, sodium and calcium channel blockers, acetylcholine, metabolic inhibition and ischemia (59-61,89-103) Injection of potassium salts into blood perfusing the coronary arteries (125) or into subepicardium (126,127) Potassium chloride application on the pericardial surface (128) Right ventricular infarction (129) 
Diagnostic Workup
Programmed electrical stimulation reproducibility induces VT or VF in almost all Brugada syndrome patients with a history of aborted sudden death or syncope. Positive late potentials on signal-averaged ECG are a common finding as well, particularly in patients in whom an elevated ST segment is accompanied by apparent RBBB. Because the ECG manifestations of the syndrome are often transient, the use of sodium channel blocking agents including ajmaline, procainamide and flecainide to unmask the syndrome is recommended in those in whom the syndrome is suspected (81) . Imaging techniques, endocardial biopsy and cardiac catheterization are useful in ruling out structural cardiac abnormalities. Finally, extension of the testing to family members is also important (38) because of high incidence of familial occurrence (82) .
Clinical Course and Current Concepts of the Treatment Strategy
The mean age of affected individuals is in the mid to late thirties, ranging from 4 to 70 years. All clinical manifestations of the Brugada syndrome are attributed exclusively to the life-threatening ventricular tachyarrhythmias and their complications. Tragically, in some patients sudden death is the first and only clinical event. Diagnosis and prevention of lifethreatening ventricular tachyarrhythmias and their complications are the main objective of therapy.
In the majority of cases, malignant tachyarrhythmias occur at rest and in many cases at nighttime, especially in Japan and Southeastern Asia. A sudden rise in vagal activity has been reported to occur just before VF episodes in some patients (29) , whereas abnormally high sympathetic tone has been documented in other patients 1 week after episodes of VF (51) . In some patients mental stress (18) and alcohol consumption (15) are thought to be provocative factors.
The incidence of arrhythmic events is similar in patients receiving either an implantable cardiac defibrillator (ICD), amiodarone or beta-adrenergic blocking agents. However, only patients with an ICD are protected from sudden death (29, 82) . The first randomized clinical trial of defibrillator versus treatment with beta-blockers was initiated in 1997 (17) . A cardioselective blocker of transient outward current (I to ), although not available in today's pharmacologic armamentarium, is expected to be highly effective in protecting patients with the Brugada syndrome against VT/VF (61, 81, 83) . Antiarrhythmic agents with I to blocking properties, such as quinidine, may also prove effective (2, 81) .
Thus, at present there are no specific pharmacologic treatments for preventing sudden death in patients with the Brugada syndrome. Implantation of an ICD is the only effective intervention for preventing sudden death. Of special interest are individuals displaying the ECG features of the Brugada syndrome, but without arrhythmogenic complications. Their potential risk of sudden death should be evaluated during electrophysiologic study; inducibility of VT/VF should be considered as an indication for an ICD (82) .
Possible Cellular and Ionic Mechanisms
ST segment elevation and phase 2 reentry. A down-sloping ST segment elevation similar to that observed in the Brugada syndrome is a normal characteristic of the ECG of some rodents (84) . This manifestation of the ECG is due to a much earlier repolarization of the epicardial action potential due to a more intense I to (85) . Accordingly, block of I to with 4-aminopyridine normalizes the Accent Potential Duration (APD) of rat/mouse epicardium and endocardium, yielding an isoelectric ST segment (86 -88) .
An isoelectric ST segment is a normal feature of the ECG in higher mammals. This is due to the fact that the voltage of the early part of phase 2 of the action potential is relatively similar throughout the myocardium, due to the development of a prominent calcium current (I Ca )-mediated action potential plateau. The development of a normal plateau phase is dependent on the balance of currents active at the end of phase 1; usually this balance is predominantly inward due to a strong I Ca and relatively weak toward currents such as I to . Under pathophysiologic conditions, the balance of current active at the end of phase 1 can shift outward, causing a loss of the action potential dome. This occurs when the contribution of inward currents at the end of phase 1 is relatively weak and that of the outward currents is relatively strong. Pathophysiologic conditions (e.g., ischemia, metabolic inhibition) and some pharmacologic interventions (e.g., sodium current [I Na ] or I Ca blocking agents or adenosine triphosphate-sensitive potassium current [I K-ATP ] activators) are capable of causing a marked abbreviation of the action potential in canine and feline ventricular epicardial cells, where I to is prominent, but not endocardial cells. Under these conditions, the ECG displays an ST segment elevation similar to that observed in patients with the Brugada syndrome.
Most of the characterization of this phenomenon and its arrhythmic sequelae is the result of work conducted in the canine heart (59 -61,89 -103) . The presence of a prominent I to -mediated notch predisposes canine ventricular epicardium to all-or-none repolarization and phase 2 reentry. Under ischemic conditions and in response to a variety of drugs, including sodium and calcium channel blocking agents, canine ventricular epicardium exhibits an all-or-none repolarization as a result of the rebalancing of currents flowing at the end of phase 1 of the action potential. Failure of the dome to develop occurs when the outward currents (principally I to ) overwhelm the inward currents (chiefly I Ca ), resulting in a marked (40% to 70%) abbreviation of the action potential (59 -61,89 -103) . Under these conditions the action potential plateau (dome) is usually abolished at some epicardial sites but not others, causing a marked dispersion of repolarization. Propagation of the action potential dome from sites at which it is maintained to sites at which it is abolished can cause local reexcitation of the preparation. This mechanism, termed phase 2 reentry, produces closely coupled extrasystolic beats, which can then initiate one or more cycles of circus movement reentry (92) ( Figs. 2 and 3 ). Under ischemic conditions ( Figs. 2 and 3 ) the contribution of I Ca is reduced, thus shifting the balance of current at the end of phase 1 to net outward in canine epicardium (92) . Similar electrical heterogeneity leading to phase 2 reentry occurs in canine epicardium exposed to: a) K ϩ channel openers such as pinacidil (96); b) sodium channel blockers such as flecainide (97); c) increased [Ca 2ϩ ] o (95), and d) metabolic inhibition (100) . Because the level of I to is pivotal, I to block restores electrical homogeneity and abolishes reentrant activity in all cases (Fig. 3) .
Phase 2 reentry as a trigger for idiopathic ventricular fibrillation. As already discussed, loss of the action potential dome (plateau) in epicardium but not endocardium would be expected to cause elevation of the ST segment, similar to that found in patients with the Brugada syndrome (98,100). Because loss of the dome is caused by an outward shift in the balance of currents active at the end of phase 1 of the action potential (principally I to and I Ca ), autonomic neurotransmitters like acetylcholine facilitate loss of the action potential dome (101) by suppressing calcium current and augmenting potassium current, whereas beta-adrenergic agonists such as isoproterenol and dobutamine restore the dome by augmenting I Ca . Sodium channel blockers also facilitate loss of the canine right ventricular action potential dome as a result of a negative shift in the voltage at which phase 1 begins (97, 102) .
Accentuation of the ST segment elevation in patients with the Brugada syndrome following vagal maneuvers or sodium channel blockers, as well as normalization of the ST elevation following beta-adrenergic agents are concordant with the findings in isolated tissue preparations (50, 60) . The appearance of the ST segment elevation only in right precordial leads in patients with the Brugada syndrome is also consistent with the observation that loss of the action potential dome is much more easily induced in right than left canine ventricular epicardium (98,100) because of the higher density of I to in Figure 3 . Phase 2 reentry-initiated circus movement tachycardia abolished with transient outward current inhibition. (A) Exposure of canine right ventricular epicardial sheet to simulated ischemia results in loss of the dome at sites 3 and 4 but not at sites 1 and 2 (basic cycle length ϭ 1100 ms). Conduction of the basic beat proceeds normally from the stimulation site (site 2; see schematic a). Propagation of the action potential dome from the right half of the preparation causes reexcitation of the left half via a phase 2 reentry mechanism (see schematic b). The extrasystolic beat generated by phase 2 reentry then initiates a run of tachycardia that is sustained for four additional cycles via a typical (phase 0) circus movement reentry mechanism. The proposed reentrant path is shown in Schematic c. Note that phase 2 reentry provides an activation front roughly perpendicular to that of the basic beat. Microelectrode recordings were obtained from four sites as shown in the schematic (upper right). After 35 min of ischemia, the action potential dome develops normally at site 4, but not at sites 1, 2 or 3. The dome then propagates in a clockwise direction, reexciting sites 3, 2 and 1 with progressive delays, thus generating a reentrant extrasystole with a coupling interval of 156 ms at site 1. basic cycle length ϭ 700 ms. A similar phenomenon is observed upon exposure of right ventricular epicardium to acetylcholine, potassium channel openers and inhibitors of sodium and calcium inward currents. Adapted with permission from Lukas and Antzelevitch (92) . GUSSAK ET AL. JACC Vol. 33, No. 1 THE BRUGADA SYNDROME January 1999: [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] right than left ventricular epicardium (103, 104) . These similarities in electrophysiology, pharmacology and ECG have prompted us to speculate that a depressed right ventricular epicardial action potential dome underlies the ST segment elevation and that phase 2 reentry may provide the trigger for episodes of ventricular fibrillation in patients with the Brugada syndrome (81) . A test of these hypotheses has recently been performed in arterially perfused canine right ventricular wedge preparations. Preliminary results using the perfused wedge preparation support the hypothesis that ST segment elevation in patients with the Brugada syndrome may be the result of loss of the action potential dome in right ventricular epicardium, where I to is most prominent, but not in endocardium, where I to is weak. Initiation of VT/VF under these conditions is via phase 2 reentry secondary to heterogeneous loss of the epicardial action potential dome (59) . The VT generated in these preparations was sometimes polymorphic, resembling a rapid form of Torsade de Pointes (TdP). This activity may be mechanistically related to the migrating spiral wave shown by Pertsov et al. (105) to generate a pattern resembling TdP associated with a normal QT interval. Both in the perfused wedge and in isolated tissues, agents that inhibit I to , including 4-aminopyridine, quinidine and disopyramide, proved effective in restoring the action potential dome, thus restoring electrical homogeneity and aborting all arrhythmic activity. Thus class I antiarrhythmic agents that block I Na much more potently than I to (procainamide, ajmaline and flecainide) appear to unmask or exacerbate the ECG pattern of the Brugada syndrome, whereas those with actions to block both I Na and I to (quinidine and disopyramide) exert an ameliorative effect.
For these concepts to be considered as applicable to humans, it is important to demonstrate the presence of a large I to in human epicardium but not endocardium. Two separate studies have shown these distinctions in myocytes isolated from the respective regions of the human heart (106, 107) . An important difference between man and dog is that I to reactivation is much faster in human epicardium than in the dog epicardium, suggesting that electrical heterogeneity and phase 2 reentry might occur over a much wider range of heart rates and be less influenced by heart rate in the human ventricle.
Candidate genes for the Brugada syndrome. One of the easiest means to induce ST segment elevation and phase 2 reentry in isolated epicardial tissue preparations is through block of the sodium channel. Sodium channel blockers facilitate loss of the canine right ventricular action potential dome as a result of a negative shift in the voltage at which phase 1 begins (97, 102) . Gene mutations that diminish the density or conductance of the sodium channel are therefore prime candidates. Such mutations would also be consistent with the conduction disturbances that sometimes accompany the Brugada syndrome. Based on the results discussed above, other candidates include gene mutations that alter the intensity or kinetics of either I to or I Ca so as to augment the activity of the former and diminish that of the latter during the early phases of the action potential. Genes of autonomic receptors that modulate the activity or expression of these channels as well as those that regulate I K-ATP are candidates as well.
The first gene to be linked to the Brugada syndrome was reported in early 1998. Chen and colleagues in the laboratory of Drs. Wang and Towbin studied six small families and two sporadic cases of the Brugada syndrome using molecular genetic methods. Based on the presumed pathophysiology leading to the electrocardiographic findings, a candidate gene approach was taken. A variety of ion channels were screened for mutations and, in three families, mutations in the cardiac sodium channel gene, SCN5A, the same gene responsible for LQT3, were identified ( Fig. 4) (55) . It should be emphasized that the mutations were at sites other than those known to contribute to the LQT3 form of the long QT syndrome, and the QT interval was not prolonged in these patients (Fig. 5 ). The mutations encountered in the Brugada syndrome patients caused either an acceleration of the recovery of the sodium channel (missense mutation) or nonfunctional sodium channels (insertion and deletion mutations). Electrophysiologically these mutations are thought to cause VF due to heterogeneity of the refractory period caused by the presence of both normal and mutated sodium channels in the same tissue (i.e., in the case of the missense mutation) or by the reduction in the number of functional sodium channels (as seen in the deletion and insertion mutants), which as previously discussed would be expected to promote the development of reentrant arrhythmias.
SCN5A was excluded as the gene causing the Brugada syndrome in at least one family, leading to the speculation that genetic heterogeneity exists in the Brugada syndrome. These findings provide further support for a primary electrical disease as the basis for the Brugada syndrome form of idiopathic VT/VF.
Summary and Future Directions
The available data suggest that the Brugada syndrome is a familial primary electrical disease caused by a defect in an ion channel gene, resulting in premature repolarization of some right ventricular epicardial sites. The resulting transmural repolarization gradient underlies the phenotypic ST segment elevation, and the intraepicardial dispersion of repolarization gives rise to closely coupled phase 2 reentrant extrasystoles that can precipitate VT/VF. Patients at risk often show periodic normalization of the ST segment, leading to underestimation of the syndrome. Sodium channel blockers can be used to unmask the syndrome and should be avoided by Brugada patients unless they also significantly block I to . Implantable cardiac defibrillator implantation is the only unequivocally effective treatment and should be considered in symptomatic and asymptomatic individuals with positive electrophysiologic testing. These observations notwithstanding, our knowledge of this and other idiopathic VF syndromes remains scant. Future studies will be aimed at further genetic linkage analysis of large families affected by the Brugada syndrome to examine the full scope of the genetic basis for the disease as well as to assess pharmacologic therapy using I to blockers and other agents.
We are indebted to Drs. Pedro Brugada, Josep Brugada and Ramon Brugada for their helpful comments. Our special appreciation for Dr. Yasuhiro Yokoyama for helping with translation from Japanese. Figure 5 . The predicted secondary structure of the cardiac sodium channel and locations of mutations causing the Brugada syndrome and chromosome 3-linked long QT syndrome. The channel consists of four putative transmembrane domains (DI-DIV), with each domain containing six transmembrane segments (S1-S6). The Brugada syndrome mutations are shown in circles with dark lettering and long QT syndrome-associated mutations are in circles with white lettering. Adapted with permission from Chen et al. (55) .
